IceCure Medical (NASDAQ:ICCM – Get Free Report) and Ardent Health (NYSE:ARDT – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
Risk and Volatility
IceCure Medical has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Ardent Health has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.
Earnings and Valuation
This table compares IceCure Medical and Ardent Health”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IceCure Medical | $3.38 million | 8.62 | -$15.06 million | ($0.24) | -1.50 |
| Ardent Health | $6.32 billion | 0.22 | $135.81 million | $0.96 | 10.31 |
Ardent Health has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Ardent Health, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
0.6% of IceCure Medical shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 1.7% of Ardent Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares IceCure Medical and Ardent Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IceCure Medical | -445.61% | -221.04% | -118.89% |
| Ardent Health | 2.15% | 14.30% | 4.58% |
Analyst Recommendations
This is a breakdown of recent recommendations for IceCure Medical and Ardent Health, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IceCure Medical | 1 | 1 | 1 | 0 | 2.00 |
| Ardent Health | 2 | 5 | 7 | 0 | 2.36 |
IceCure Medical presently has a consensus target price of $2.64, indicating a potential upside of 633.98%. Ardent Health has a consensus target price of $14.25, indicating a potential upside of 43.98%. Given IceCure Medical’s higher probable upside, equities research analysts clearly believe IceCure Medical is more favorable than Ardent Health.
Summary
Ardent Health beats IceCure Medical on 10 of the 14 factors compared between the two stocks.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
About Ardent Health
Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
